Navigation Links
Angioplasty Not Always Worth the Price
Date:11/12/2008

Cost analysis finds procedure often doesn't bring enough benefit to offset expense

WEDNESDAY, Nov. 12 (HealthDay News) -- The high cost of angioplasty may not justify the marginal benefit, a new study suggests.

Researchers reporting at the American Heart Association's (AHA) annual scientific sessions in New Orleans found that adding angioplasty to optimal medical therapy improved angina-related symptoms in some patients but "at a cost generally considered to be prohibitive as a routine initial management strategy."

"This is an important trial," said Dr. Sidney Smith, chairman of the AHA/American College of Cardiology task force on guidelines. "More and more as we develop guidelines and treatment strategies for patients, the cost is important, and in this particular trial, it appeared the use of stents and additional angina associated with that was expensive."

But this doesn't mean the procedure shouldn't be performed.

"Cost should not be a total roadblock," Smith said. "It should be an incentive to do things in a better way, by targeting the population or making the procedure or drug in a less expensive way. . . . Let's find a way to fix the cost."

Currently, cost analyses of procedures and medications tend to lag behind studies of their effectiveness and place in the practice of medicine.

Prior research suggests that interventional procedures to re-open coronary arteries after blockages, when used with up-to-date medical therapy, does not actually reduce the incidence of cardiovascular events any more than medication alone.

The original trial, known as COURAGE, compared adding angioplasty to best medical therapy and lifestyle interventions to medical therapy alone in reducing the risk of dying or having a heart attack. It found little difference between the two.

According to the AHA, angioplasty involves inserting a thin tube from a groin artery to the blocked artery in the heart. Doctors then inflate a small balloon at the tip of the tube to widen the vessel, insert a stent and restore blood flow.

This secondary analysis involved 2,287 patients who were followed for a median of 4.6 years. Researchers compared the cost of treating angina in Canada, the U.S. non-VA health system and the U.S. VA health system.

Quality of life results were similar among groups, although physical limitation results did vary. The net benefit here ranged from less than 1 percent in U.S. non-VA hospitals to 18 percent in Canadian facilities.

When measured by the frequency of chest pain, researchers calculated the absolute net benefit to be 6.85 percent, with an average added cost for the PCI of $10,107 per patient.

The added cost of PCI ranged from a low of $5,906 per patient in Canada to a high of $15,896 in U.S. VA hospitals.

The overall cost per patient related to angina frequency (as assessed by a patient questionnaire) ranged from a low of $55,700 in Canada (the average in Canada was $118,740) to a high of more than $1 million at U.S. non-VA facilities. The analysis was done in 2004 U.S. dollars.

More information

The American Heart Association has more on angioplasty.



SOURCES: Sidney Smith, Jr., M.D., past president, American Heart Association, and professor, medicine, University of North Carolina, Chapel Hill; Nov. 12, 2008, presentation, American Heart Association annual scientific sessions, New Orleans


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hispanics less likely to have repeat revascularizations 1 year after angioplasty
2. Florida study finds barriers to angioplasty for life-threatening heart attacks
3. Angioplasty Scoring System Predicts Risk of Death
4. Angioplasty No Better Than Drug Treatment in Long Run
5. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
6. Off-Hours Heart Patients Less Likely to Get Angioplasty
7. State Report Ranks LIJ as New Yorks Best Hospital for Angioplasty Survival
8. Angioplasty Proves Reasonable Alternative to Bypass Surgery
9. Anticoagulant Drugs Had Similar Outcomes After Angioplasty
10. Comparison of anticoagulants for angioplasty show similar outcomes
11. The Elderly Can Be Candidates for Angioplasty, Stenting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Angioplasty Not Always Worth the Price
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: